-
Mashup Score: 0Exclusive highlights in genitourinary cancer at ASCO 2023 - 7 month(s) ago
Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, provides important updates in genitourinary cancer at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including findings from the PEACE-1 trial (NCT01957436), as well as updates in PARP inhibitors with radioligands in prostate cancer. Dr Barata additionally comments on trials assessing salvage chemotherapy in renal cell carcinoma (RCC) and targeting EGFR in bladder cancer. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Sara Hurvitz, MD, discusses updates of the EMERALD trial investigating elacstrant vs the standard of care, including the subgroups of patients who received prior CDK4/6 inhibition for 6, 12, or 18 months.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sara Hurvitz, MD, discusses updates of the EMERALD trial of #elacstrant vs the standard of care, including the subgroups of patients who received prior CDK4/6 inhibition for 6, 12, or 18 months. #bcsm #SABCS22 https://t.co/K8pm6UfM4H
-
-
Mashup Score: 2NanoString: Intrinsic Subtypes and 21-Gene Assay Predict ... - 1 year(s) ago
NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya Chumsri, MD Breast cancer is a complex disease with many different subtypes that can impact treatment decisions and patient outcomes. HER2-positive breast cancer is a subtype tha…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Saranya Chumsri discusses the effects of intrinsic subtypes and the 21-gene assay on recurrence risks in patients with early stage HER2+ breast cancer. @SaranyaChumsri @MayoClinic #SABCS22 Read and Share the Article Here: https://t.co/b1FnMutIJy https://t.co/1IX5Vffcew
-
-
Mashup Score: 0Invasive Lobular Breast Cancer: Steffi Oesterreich Shares... - 1 year(s) ago
Invasive Lobular Breast Cancer: Steffi Oesterreich Shares Insightful Learning Sessions Exploring ILBC at SABCS 2022 By Steffi Oesterreich, PhD So, I was very excited about increasing attention to special subtypes of breast cancer. There was actually a unique session, an educational session called Challenging Types o…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Steffi Oesterreich recently shared insightful learning sessions exploring invasive lobular breast cancer (ILBC) at SABCS 2022. @oesterreichs @PittTweat #SABCS22 Listen and Share the Audio Podcast Here: https://t.co/gq9dSS67PN https://t.co/OK6AOJwpBq
-
-
Mashup Score: 0Leptomeningeal Disease: Phase 1 Trial of BBB-Penetrant HE... - 1 year(s) ago
Leptomeningeal Disease: Phase 1 Trial of BBB-Penetrant HER2 Inhibitor in Metastatic Breast Cancer Nicholas McAndrew MD By Nicholas McAndrew, MD, MSCE DZD1516 is a is a new compound, it’s a new oral tyrosine kinase inhibitor that was designed by the company. When the company initially was developing this drug. They w…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out this informative video featuring Dr. McAndrew, as he discusses the Phase 1 trial of a BBB-penetrant HER2 inhibitor for treating leptomeningeal disease in metastatic breast cancer. @UCLAHealth @dgsomucla #SABCS22 Watch and Share the Video Here: https://t.co/epnmVLrmJE https://t.co/oV2W4PEJhE
-
-
Mashup Score: 0Polygenic Risk Score: Validation of a Breast Cancer Risk ... - 1 year(s) ago
Polygenic Risk Score: Validation of a Breast Cancer Risk Prediction Model in a Large Prospective Cohort Thomas Slavin, MD By Thomas Slavin, MD When we think about polygenic risk score, it is fairly new. We are doing a lot of the innovation at Myriad. We’ve been doing a lot to restructure the company focused down on …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new study by Myriad Genetics, discussed by Dr. Thomas Slavin, has just been published, reporting on the prospective longitudinal validation of a breast cancer risk prediction model. @SlavinTj @MyraidOncology #SABCS22 Watch and Share the Video Here: https://t.co/QTUJNl4Yy9 https://t.co/GJaIcsk7g0
-
-
Mashup Score: 0Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benef... - 1 year(s) ago
Endocrine Therapy: 70-Gene MammaPrint Test Predicts Benefit in Early-Stage Breast Cancer Laura Van ’t Veer By Laura Van ‘t Veer, MSC, PhD Breast cancer patients who are diagnosed with breast cancer that is endocrine sensitive. So those tumors that are estrogen receptor positive, their standard of treatment is …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Laura Van 't Veer, PhD, discussed a recent IDEAL Trial that highlights the utility of the 70-gene MammaPrint test. @LVVPrint @mammaprint @UCSF @UCSFCancer #SABCS22 #BreastCancer Watch and Share the Video Here: https://t.co/tkKFARmUtd https://t.co/5HfrFyPyoB
-
-
Mashup Score: 0PACE Trial: Palbociclib, Fulvestrant, and Avelumab in End... - 1 year(s) ago
PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So a very important standard of care for our patients with metastatic hormone receptor positive HER2-negative breast cancer is using a CDK4/6 inhibitor in combination with endocrine …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Erica Mayer, MD, discusses the results of the PACE trial, which evaluated the use of palbociclib, fulvestrant, and avelumab in patients with endocrine pre-treated metastatic breast cancer. @elmayermd @danafarber #SABCS22 Watch and Share the Video Here: https://t.co/XJUYDb6Ct8 https://t.co/BhbyEWHNrz
-
-
Mashup Score: 0NanoString: Intrinsic Subtypes and 21-Gene Assay Predict ... - 1 year(s) ago
NanoString: Intrinsic Subtypes and 21-Gene Assay Predict Recurrence in Early Stage HER2+ Breast Cancer from Saranya Chumsri MD By Saranya Chumsri, MD Breast cancer is a complex disease with many different subtypes that can impact treatment decisions and patient outcomes. HER2-positive breast cancer is a subtype that…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Saranya Chumsri discusses the effects of intrinsic subtypes and the 21-gene assay on recurrence risks in patients with early stage HER2+ breast cancer. @SaranyaChumsri @MayoClinic #SABCS22 Watch and Share the Video Here: https://t.co/D8ORg6vVeu https://t.co/i1omRu5TnT
-
-
Mashup Score: 0PACE Trial: Palbociclib, Fulvestrant, and Avelumab in End... - 1 year(s) ago
PACE Trial: Palbociclib, Fulvestrant, and Avelumab in Endocrine Pre-treated Metastatic Breast Cancer Erica Mayer MD By Erica Mayer, MD So a very important standard of care for our patients with metastatic hormone receptor positive HER2-negative breast cancer is using a CDK4/6 inhibitor in combination with endocrine …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Discover the latest research findings on Palbociclib After CDK4/6i and Endocrine Therapy (PACE) for ER+/HER2- metastatic breast cancer, by Dr. Erica Mayer. @elmayermd @danafarber #SABCS22 Watch and Share the Video Here: https://t.co/z2TcaIS7YZ https://t.co/PyVt8DzJh2
-
📣October is Breast Cancer Awareness Month 📅 Check out this interview with @PTarantinoMD from #SABCS22, where he discusses the remaining questions surrounding HER2-low breast cancer – how low can you go? ➡️https://t.co/rMKoTK5huk🎥 #BCSM https://t.co/e7Cl16XAbt